The United States authorized a COVID-19 test that is carried out by blowing into a tube

The InspectIR COVID-19 Breathalyzer was the subject of a study with 2,409 volunteers and is reliable in areas with low incidence of the disease

Guardar
A staff member demonstrates the
A staff member demonstrates the usage of Breathonix breathalyzer test kit developed by Breathonix, a start-up by the National University of Singapore, able to detect the coronavirus disease (COVID-19) within a minute according to the company, at their laboratory in Singapore October 29, 2020. REUTERS/Chen Lin

The US Food and Drug Administration (FDA) approved this Thursday for the first time a covid-19 test that is done by blowing.

The so-called InspectIR COVID-19 Breathalyzer detects the chemical components that exist in the breath samples that are taken and that are associated with that disease, the FDA explained in a statement.

The test is done by blowing into a tube that is connected to a device that is shaped like a balloon and that captures the sample.

The FDA explained that this type of test can be done in places such as clinics, hospitals and mobile sites for covid testing, under the supervision of specialized personnel, and it takes three minutes to produce a result.

An FDA official, Jeff Shuren, said in the note that today's authorization “is another example of rapid innovation on covid-19 testing.”

The new test uses a technique called Gas Chromatography coupled to Mass Spectrometry (GC/MS), which serves to separate and identify combined chemicals and that quickly detects five volatile organic compounds linked to covid infection.

When the test finds the presence of markers of these organic compounds, it gives a positive result, which, according to the FDA, should then be confirmed by a molecular test.

The test was the subject of a study with 2,409 volunteers, with and without symptoms of covid-19, and in which it was shown that the test had a sensitivity of 91.2%, a percentage that refers to the positives that InspectIR COVID-19 Breathalyzer correctly identified.

In addition, the test had 99.3% specificity, which is the rate of negatives that the test correctly detected.

The analysis also showed that in a population with only 4.2% of infected individuals, the test had a predictive value of 99.6%, which means that it is reliable in areas with low incidence of the disease.

(With information from EFE)

Keep reading: